Polaramine 2 mg tablets

Patient Information Leaflet

Introduction

Patient Information Leaflet

Polaramine 2 mg tablets

Dexchlorpheniramine maleate

Read the entire leaflet carefully before you start taking this medicine, as it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet Contents

1. What Polaramine is and what it is used for
2. What you need to know before taking Polaramine
3. How to take Polaramine
4. Possible adverse effects
5. How to store Polaramine
6. Contents of the pack and other information

1. What Polaramine is and what it is used for

Dexchlorpheniramine belongs to a group of medicines known as antihistamines.

Polaramine is indicated for the symptomatic treatment of seasonal and perennial allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild uncomplicated cutaneous allergic manifestations such as urticaria and angioedema, and reactions to blood or plasma. It is also indicated in the treatment of anaphylactic reactions in conjunction with adrenaline or other appropriate measures, after controlling the acute manifestations. Polaramine often relieves cutaneous manifestations such as allergic eczema, atopic and contact dermatitis, insect bites, dermographism, and drug reactions.

2. What you need to know before taking Polaramine

Do not take Polaramine

• if you are allergic to dexchlorpheniramine maleate or any of the other ingredients of this medicine (listed in section 6).
• Polaramine must not be administered to newborns and premature infants.
• If you are being treated with a special type of antidepressants known as monoamine oxidase inhibitors (MAO inhibitors), or during the two weeks following discontinuation of such treatment.

Warnings and precautions

Talk to your doctor or pharmacist before taking Polaramine:

• if you have narrow-angle glaucoma, a certain type of stomach ulcer (obstructive), pyloroduodenal obstruction, prostate disorders, urinary bladder neck obstruction, cardiovascular diseases including high blood pressure, or if you have increased intraocular pressure or thyroid disorders.
• if you are over 60 years of age, as in patients over 60 years, Polaramine may cause dizziness, sedation, and low blood pressure.

Children

The safety and efficacy of Polaramine have not been established in children under 6 years of age, and therefore it should not be administered to these patients. Polaramine may cause nervousness and restlessness, especially in children.

Taking Polaramine with other medicines

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

A special type of antidepressants known as monoamine oxidase inhibitors (MAO inhibitors) prolong and intensify the effect of antihistamines, possibly causing severe hypotension, i.e. a serious drop in blood pressure.

Concomitant use of Polaramine with tricyclic antidepressants, barbiturates, or other medicines acting on the central nervous system may enhance the sedative effect of Polaramine.

Medicines of the Polaramine group (antihistamines) may reduce the effect of oral anticoagulants; therefore, you should consult your doctor before taking Polaramine.

Taking Polaramine with food, drinks, and alcohol

Concomitant use of Polaramine with alcohol may enhance the sedative effect of Polaramine.

Interaction with laboratory tests

Treatment with Polaramine should be discontinued at least 48 hours before performing any skin allergy tests, as medicines of the Polaramine group (antihistamines) may mask the results of these tests.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor before using this medicine.

Pregnancy

Polaramine must not be administered during the third trimester of pregnancy, as newborns and premature infants may experience severe adverse reactions to antihistamines.

During the first two trimesters of pregnancy, Polaramine should be used only if considered necessary by your doctor.

Breastfeeding

It is unknown whether Polaramine is excreted in human milk; therefore, consult your doctor if you are breastfeeding.

Driving and use of machines

Polaramine may cause drowsiness, affecting mental and/or physical abilities. If you experience these effects, avoid driving vehicles or operating machinery.

Polaramine contains lactose

This medicine contains lactose. If your doctor has informed you that you have an intolerance to certain sugars, consult with him before taking this medicine.

3. How to take Polaramine

Follow exactly the instructions for use provided by your doctor. If in doubt, consult your doctor or pharmacist again.

Your doctor will determine your individual dose according to your disease requirements and your response.

In adults and children aged 12 years and older: the recommended dose is one tablet 3 or 4 times daily, up to a maximum of 6 tablets per day.

Use in children

Children aged 6 to 12 years: a maximum total of 3 tablets divided into three doses.

Swallow the tablets with a sufficient amount of liquid – a glass of water.

If you take more Polaramine than you should

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service, telephone (91) 562 04 20, indicating the medication and the amount ingested.

If you forget to take Polaramine

Do not take a double dose to make up for missed doses.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine may cause adverse effects, although not everyone will experience them.

The most frequently observed adverse effect with the use of Polaramine (antihistamines) is mild to moderate drowsiness. General adverse effects reported include urticaria, skin rash, severe allergic reactions (anaphylactic shock), photosensitivity, excessive sweating, chills, dryness of mouth, nose, and throat.

Other adverse effects that may occur with the use of antihistamines include: cardiovascular reactions, blood disorders, nervous system reactions, gastrointestinal reactions, genitourinary reactions, and respiratory reactions.

Reporting of adverse effects:

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly through the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Polaramine

Keep this medicine out of sight and reach of children.

This medicine does not require any special storage conditions.

Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date refers to the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Dispose of containers and unused medicines at the SIGRE collection point at your pharmacy. If you have any doubts, ask your pharmacist how to properly dispose of unused medicines and their containers. This will help protect the environment.

6. Contents of the package and other information

Composition of Polaramine

• The active substance is dexchlorpheniramine maleate. Each Polaramine tablet contains 2 mg of dexchlorpheniramine maleate.
• The other components are lactose, pregelatinized starch (from corn), corn starch, magnesium stearate, and purified water.

Appearance of the product and contents of the pack

White, round, flat tablets with bevelled edges, scored on one side.

Each pack contains 20 tablets.

Marketing Authorization Holder and Manufacturer

Manufacturer

ROVI Pharma Industrial Services, S.A.

Vía Complutense, 140,

Alcalá de Henares, 28805

Madrid

Spain

Date of the most recent review of this leaflet: March 2007

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/